Zura Bio Limited (ZURA)
- Previous Close
3.6200 - Open
3.6800 - Bid 4.3700 x 200
- Ask 4.4400 x 300
- Day's Range
3.6800 - 4.8300 - 52 Week Range
2.0000 - 14.0000 - Volume
895,310 - Avg. Volume
301,579 - Market Cap (intraday)
274.858M - Beta (5Y Monthly) 0.54
- PE Ratio (TTM)
-- - EPS (TTM)
-2.0900 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
16.40
Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada.
zurabio.comRecent News: ZURA
Performance Overview: ZURA
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ZURA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ZURA
Valuation Measures
Market Cap
274.86M
Enterprise Value
275.20M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
4.63
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-4.39
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-73.79%
Return on Equity (ttm)
-173.05%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-69.24M
Diluted EPS (ttm)
-2.0900
Balance Sheet and Cash Flow
Total Cash (mrq)
99.81M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-25.08M